Bellicum Pharmaceuticals, Inc. (BLCM) |
|
1.2591 0.079 (6.7%)
|
02-03 15:01 |
|
Open: |
1.1874 |
Pre. Close: |
1.18 |
|
High:
|
1.3 |
Low:
|
1.18 |
|
Volume:
|
38,523 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:15:44 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.75 One year: 2.04 |
| Support: |
Support1: 0.94 Support2: 0.6 |
| Resistance: |
Resistance1: 1.5 Resistance2: 1.75 |
| Pivot: |
1.2 |
| Moving Average: |
MA(5): 1.21 MA(20): 1.16
MA(100): 1.05  MA(250): 1.31 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 54.1 %D(3): 49.9 |
| RSI: |
RSI(14): 58.4 |
| 52-week: |
High: 2.2 Low: 0.6 |
| Average Vol(K): |
3-Month: 41 (K) 10-Days: 62 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BLCM ] has closed below upper band by 36.8%. Bollinger Bands are 60.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.25 - 1.26 |
1.26 - 1.26 |
|
Low:
|
1.14 - 1.15 |
1.15 - 1.16 |
|
Close:
|
1.17 - 1.18 |
1.18 - 1.19 |
|
Company Description |
|
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. |
Headline News |
Tue, 31 Jan 2023
CORRECTION -- Bellicum Reports Inducement Grants Under ... - InvestorsObserver
Tue, 31 Jan 2023
CORRECTION -- Bellicum Reports Inducement Grants Under ... - The Bakersfield Californian
Mon, 23 Jan 2023
Where Does Bellicum Pharmaceuticals Inc (BLCM) Stock Fall in the Biotechnology Field After It Is Higher By 47.47% This Week? - InvestorsObserver
Thu, 19 Jan 2023
Can Bellicum Pharmaceuticals Inc (BLCM) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Thu, 19 Jan 2023
NeuroSense, RenovoRx top healthcare gainers; Jupiter Wellness ... - Seeking Alpha
Sun, 11 Dec 2022
Bellicum Announces Presentation by UNC at ASH 2022 on Potential ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
7.06e+006 (%) |
|
% Held by Institutions
|
4.4 (%) |
|
Shares Short
|
108 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.472e+007 |
|
EPS Est Next Qtl
|
-0.75 |
|
EPS Est This Year
|
-3.02 |
|
EPS Est Next Year
|
-2.96 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
649.3 |
|
Return on Equity (ttm)
|
-57.7 |
|
Qtrly Rev. Growth
|
1.5e+006 |
|
Gross Profit (p.s.)
|
-57.98 |
|
Sales Per Share
|
-74.97 |
|
EBITDA (p.s.)
|
-1.25942e+007 |
|
Qtrly Earnings Growth
|
0.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-25 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
2.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
82150 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-02-05 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
